EP3883546A1 — Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
Assigned to Rosemont Pharmaceuticals Ltd · Expires 2021-09-29 · 5y expired
What this patent protects
The present application relates generally to pharmaceutical compositions comprising a pharmaceutically effective amount of topiramate particles dispersed in suspension, wherein the composition is suitable for oral delivery. The present application also relates generally to novel …
USPTO Abstract
The present application relates generally to pharmaceutical compositions comprising a pharmaceutically effective amount of topiramate particles dispersed in suspension, wherein the composition is suitable for oral delivery. The present application also relates generally to novel cold-chain stable formulations of oral liquid suspension dosage forms containing topiramate and a process for producing said oral liquid suspension dosage forms. Also disclosed are improved analytical methods for assaying complex drug formulations containing sulfamate-substituted monosaccharides.
Drugs covered by this patent
- Topamax (topiramate) · Janssen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.